Zhongren Kangbo

Zhongren Kangbo is a Beijing-based biotechnology company specializing in the development of innovative sustained-release drug delivery systems for oncology. The company's core technology focuses on interstitial chemotherapy, utilizing biodegradable implants to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic toxicity. Its lead product, Fluorouracil Sustained-release Implants (ZR-01), is approved in China for the treatment of various solid tumors, particularly those of the digestive tract and liver. By maintaining therapeutic drug levels locally for extended periods, Zhongren Kangbo aims to improve the efficacy and safety profile of traditional chemotherapy. The company continues to expand its pipeline with additional sustained-release formulations targeting a broad range of malignant tumors.